Please login to the form below

Not currently logged in


This page shows the latest antidote news and features for those working in and with pharma, biotech and healthcare.

Boston Scientific makes $4.2bn play for UK’s BTG

Boston Scientific makes $4.2bn play for UK’s BTG

BTG also has a small portfolio of pharmaceutical products, including snake bite antivenin CroFab and antidotes for digoxin overdose and methotrexate toxicity, which is something of a departure from Boston Scientific

Latest news

More from news
Approximately 1 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence, collaboration. 237.5. Portola Pharmaceuticals/  HealthCare Royalty Partners. AndexXa (andexanet alfa) - Factor Xa inhibitor antidote (phase IIIb/IV).

  • Deal Watch February 2016 Deal Watch February 2016

    merger. 106. † Portola Pharmaceuticals/ BMS| Pfizer. andexanet alfa as an antidote for apixaban and other Factor Xa inhibitors (pre-reg).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    Portola is also developing PRT 064445, which is an antidote designed to reverse the activity of factor Xa inhibitors and low molecular weight heparins. ... Idrabiotaparinux sodium has the same pentasaccharidic structure as idraparinux sodium but has an

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • How to be a patient

    We can therefore provide a service by offering impartial, code-compliant information as an antidote to the 'alt-med' lobby.  .

  • Ogilvy Healthworld

    'We have a habit of divine discontent with our performance.It is an antidote to smugness.'So said David Ogilvy.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch